Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II

Company to Host R&D Update Conference Call Following AACR Meeting

REDWOOD CITY, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the company will make four presentations at the upcoming 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020. 

Details of the planned presentations are as follows:

Poster Presentations:
Title:	SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway
Abstract:	1943
Session:	Small Molecule Therapeutic Agents
Date:	June 22, 2020
Title:	Positioning a selective, bi-steric inhibitor of mTORC1 as a combination partner in RAS-driven cancers
Abstract:	LB-113
Session:	Late-Breaking Research: Experimental and Molecular Therapeutics 2
Date:	June 22, 2020
Title:	Dual inhibition of SHP2 and CDK4/6 leads to immunological memory and immune-mediated anti-tumor activity in a mouse syngeneic model of breast cancer
Abstract:	2837
Session:	Tumor-Immune System Interactions 2
Date:	June 22, 2020

Educational Session Presentation:

Title:	Discovery and development of allosteric inhibitors of SHP2
Session:	Chemistry to the Clinic: Part 1: Lead Optimization Case Studies in Cancer Drug Discovery

Additional information on the 2020 AACR Virtual Annual Meeting II is available through the AACR website at https://www.aacr.org/meeting/aacr-annual-meeting-2020/aacr-virtual-ann ...